Department of Pathophysiology, University of Berne, CH-3010 Berne,
Switzerland
I. Introduction
II. Chemistry
III. Effects in Vivo
A.Inhibition of calcification
B. Inhibition of bone resorption
C. Effects on bone formation
D. Effects on noncalcifiedtissues
IV. Mechanisms of Action
A. Calcification
B. Boneresorption
C. Other effects
V. Pharmacokinetics
VI. AnimalToxicology and Human Adverse Events
A. Animal toxicology
B.Human adverse events
VII. Conclusion
This article has been cited by other articles:
G. SPIZZO, A. SEEBER, and M. MITTERER Routine Use of Pamidronate in NSCLC Patients with Bone Metastasis: Results from a Retrospective Analysis
Anticancer Res,
December 1, 2009;
29(12):
5245 - 5249.
[Abstract][Full Text][PDF]
S. N. Gebara and H. Moubayed Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates
Am. J. Health Syst. Pharm.,
September 1, 2009;
66(17):
1541 - 1547.
[Abstract][Full Text][PDF]
C. Panaroni, R. Gioia, A. Lupi, R. Besio, S. A. Goldstein, J. Kreider, S. Leikin, J. C. Vera, E. L. Mertz, E. Perilli, et al. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta
Blood,
July 9, 2009;
114(2):
459 - 468.
[Abstract][Full Text][PDF]
R. Villa-Bellosta and V. Sorribas Phosphonoformic Acid Prevents Vascular Smooth Muscle Cell Calcification by Inhibiting Calcium-Phosphate Deposition
Arterioscler Thromb Vasc Biol,
May 1, 2009;
29(5):
761 - 766.
[Abstract][Full Text][PDF]
F. LUMACHI, A. BRUNELLO, A. ROMA, and U. BASSO Cancer-induced Hypercalcemia
Anticancer Res,
May 1, 2009;
29(5):
1551 - 1555.
[Abstract][Full Text][PDF]
T. TANAKA, H. KAWASHIMA, K. OHNISHI, K. MATSUMURA, R. YOSHIMURA, M. MATSUYAMA, K. KURATSUKURI, and T. NAKATANI Indirect Antitumor Effects of Bisphosphonates on Prostatic LNCaP Cells Co-cultured with Bone Cells
Anticancer Res,
April 1, 2009;
29(4):
1089 - 1094.
[Abstract][Full Text][PDF]
N. D. Toussaint, G. J. Elder, and P. G. Kerr Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue
Clin. J. Am. Soc. Nephrol.,
January 1, 2009;
4(1):
221 - 233.
[Abstract][Full Text][PDF]
P. D. Ottewell, H. Monkkonen, M. Jones, D. V. Lefley, R. E. Coleman, and I. Holen Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer
J Natl Cancer Inst,
August 20, 2008;
100(16):
1167 - 1178.
[Abstract][Full Text][PDF]
N Walji, A K Chan, and D R Peake Common acute oncological emergencies: diagnosis, investigation and management
Postgrad. Med. J.,
August 1, 2008;
84(994):
418 - 427.
[Abstract][Full Text][PDF]
T. B. Dodson, N. S. Raje, P. A. Caruso, and A. E. Rosenberg Case 9-2008 -- A 65-Year-Old Woman with a Nonhealing Ulcer of the Jaw
N. Engl. J. Med.,
March 20, 2008;
358(12):
1283 - 1291.
[Full Text][PDF]
L. Tauchmanova, A. Colao, G. Lombardi, B. Rotoli, and C. Selleri REVIEW: Bone Loss and Its Management in Long-Term Survivors from Allogeneic Stem Cell Transplantation
J. Clin. Endocrinol. Metab.,
December 1, 2007;
92(12):
4536 - 4545.
[Abstract][Full Text][PDF]
Y. Hacchou, T. Uematsu, O. Ueda, Y. Usui, S. Uematsu, M. Takahashi, T. Uchihashi, Y. Kawazoe, T. Shiba, S. Kurihara, et al. Inorganic Polyphosphate: a Possible Stimulant of Bone Formation
Journal of Dental Research,
September 1, 2007;
86(9):
893 - 897.
[Abstract][Full Text][PDF]
L. V. Virkki, J. Biber, H. Murer, and I. C. Forster Phosphate transporters: a tale of two solute carrier families
Am J Physiol Renal Physiol,
September 1, 2007;
293(3):
F643 - F654.
[Abstract][Full Text][PDF]
R. A. Cahill, D. Wenkert, S. A. Perlman, A. Steele, S. P. Coburn, W. H. McAlister, S. Mumm, and M. P. Whyte Infantile Hypophosphatasia: Transplantation Therapy Trial Using Bone Fragments and Cultured Osteoblasts
J. Clin. Endocrinol. Metab.,
August 1, 2007;
92(8):
2923 - 2930.
[Abstract][Full Text][PDF]
S. Ravera, L. V. Virkki, H. Murer, and I. C. Forster Deciphering PiT transport kinetics and substrate specificity using electrophysiology and flux measurements
Am J Physiol Cell Physiol,
August 1, 2007;
293(2):
C606 - C620.
[Abstract][Full Text][PDF]
E. L. Kaijzel, G. van der Pluijm, and C. W.G.M. Lowik Whole-Body Optical Imaging in Animal Models to Assess Cancer Development and Progression
Clin. Cancer Res.,
June 15, 2007;
13(12):
3490 - 3497.
[Abstract][Full Text][PDF]
M. J. Favus Diabetes and the Risk of Osteonecrosis of the Jaw
J. Clin. Endocrinol. Metab.,
March 1, 2007;
92(3):
817 - 818.
[Full Text][PDF]
S Chiandussi, M Biasotto, F Dore, F Cavalli, M. Cova, and R Di Lenarda Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.
Dentomaxillofac. Radiol.,
July 1, 2006;
35(4):
236 - 243.
[Abstract][Full Text][PDF]
L. F. Massa, V. Bradaschia-Correa, and V. E. Arana-Chavez Immunocytochemical Study of Amelogenin Deposition during the Early Odontogenesis of Molars in Alendronate-treated Newborn Rats
J. Histochem. Cytochem.,
June 1, 2006;
54(6):
713 - 725.
[Abstract][Full Text][PDF]
T. R. Halfdanarson, W. J. Hogan, and T. J. Moynihan Oncologic Emergencies: Diagnosis and Treatment
Mayo Clin. Proc.,
June 1, 2006;
81(6):
835 - 848.
[Abstract][Full Text][PDF]
S.-B. Woo, J. W. Hellstein, and J. R. Kalmar Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Ann Intern Med,
May 16, 2006;
144(10):
753 - 761.
[Abstract][Full Text][PDF]
M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon Emerging anti-cancer molecular mechanisms of aminobisphosphonates.
Endocr. Relat. Cancer,
March 1, 2006;
13(1):
7 - 26.
[Abstract][Full Text][PDF]
M Bevilacqua, L J Dominguez, S Rosini, and M Barbagallo Bisphosphonates and atherosclerosis: why?
Lupus,
September 1, 2005;
14(9):
773 - 779.
[Abstract][PDF]
L. M. Ward, A. E. Denker, A. Porras, S. Shugarts, W. Kline, R. Travers, C. Mao, F. Rauch, A. Maes, P. Larson, et al. Single-Dose Pharmacokinetics and Tolerability of Alendronate 35- and 70-Milligram Tablets in Children and Adolescents with Osteogenesis Imperfecta Type I
J. Clin. Endocrinol. Metab.,
July 1, 2005;
90(7):
4051 - 4056.
[Abstract][Full Text][PDF]
A. A Licata Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates
Ann. Pharmacother.,
April 1, 2005;
39(4):
668 - 677.
[Abstract][Full Text][PDF]
C. V. Odvina, J. E. Zerwekh, D. S. Rao, N. Maalouf, F. A. Gottschalk, and C. Y. C. Pak Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
J. Clin. Endocrinol. Metab.,
March 1, 2005;
90(3):
1294 - 1301.
[Abstract][Full Text][PDF]
A. F. Stewart Hypercalcemia Associated with Cancer
N. Engl. J. Med.,
January 27, 2005;
352(4):
373 - 379.
[Full Text][PDF]
Y. Mori, N. Shimizu, M. Dallas, M. Niewolna, B. Story, P. J. Williams, G. R. Mundy, and T. Yoneda Anti-{alpha}4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis
Blood,
October 1, 2004;
104(7):
2149 - 2154.
[Abstract][Full Text][PDF]
A. Lipton, A. Colombo-Berra, R. M. Bukowski, L. Rosen, M. Zheng, and G. Urbanowitz Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid
Clin. Cancer Res.,
September 15, 2004;
10(18):
6397S - 6403S.
[Abstract][Full Text][PDF]
J. Barrett, E. Worth, F. Bauss, and S. Epstein Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update
J. Clin. Pharmacol.,
September 1, 2004;
44(9):
951 - 965.
[Abstract][Full Text][PDF]
T. Hiraga, P. J. Williams, A. Ueda, D. Tamura, and T. Yoneda Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model
Clin. Cancer Res.,
July 1, 2004;
10(13):
4559 - 4567.
[Abstract][Full Text][PDF]
R. Rizzoli Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer
Ann. Onc.,
May 1, 2004;
15(5):
700 - 701.
[Full Text][PDF]
H. D. Danenberg, G. Golomb, A. Groothuis, J. Gao, H. Epstein, R. V. Swaminathan, P. Seifert, and E. R. Edelman Liposomal Alendronate Inhibits Systemic Innate Immunity and Reduces In-Stent Neointimal Hyperplasia in Rabbits
Circulation,
December 2, 2003;
108(22):
2798 - 2804.
[Abstract][Full Text][PDF]
M. Nakamura, N. Udagawa, S. Matsuura, M. Mogi, H. Nakamura, H. Horiuchi, N. Saito, B. Y. Hiraoka, Y. Kobayashi, K. Takaoka, et al. Osteoprotegerin Regulates Bone Formation through a Coupling Mechanism with Bone Resorption
Endocrinology,
December 1, 2003;
144(12):
5441 - 5449.
[Abstract][Full Text][PDF]
E. Alvarez, M. Westmore, R. J. S. Galvin, C. L. Clapp, E. L. Considine, S. J. Smith, K. Keyes, P. W. Iversen, D. M. Delafuente, S. Sulaimon, et al. Properties of Bisphosphonates in the 13762 Rat Mammary Carcinoma Model of Tumor-Induced Bone Resorption
Clin. Cancer Res.,
November 15, 2003;
9(15):
5705 - 5713.
[Abstract][Full Text][PDF]
M. Bezzi, M. Hasmim, G. Bieler, O. Dormond, and C. Ruegg Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death: EVIDENCE FOR THE SUPPRESSION OF SUSTAINED ACTIVATION OF FOCAL ADHESION KINASE AND PROTEIN KINASE B/Akt
J. Biol. Chem.,
October 31, 2003;
278(44):
43603 - 43614.
[Abstract][Full Text][PDF]
M. Coco, D. Glicklich, M. C. Faugere, L. Burris, I. Bognar, P. Durkin, V. Tellis, S. Greenstein, R. Schechner, K. Figueroa, et al. Prevention of Bone Loss in Renal Transplant Recipients: A Prospective, Randomized Trial of Intravenous Pamidronate
J. Am. Soc. Nephrol.,
October 1, 2003;
14(10):
2669 - 2676.
[Abstract][Full Text][PDF]
L. Zeitlin, F. Rauch, H. Plotkin, and F. H. Glorieux Height and Weight Development During Four Years of Therapy With Cyclical Intravenous Pamidronate in Children and Adolescents With Osteogenesis Imperfecta Types I, III, and IV
Pediatrics,
May 1, 2003;
111(5):
1030 - 1036.
[Abstract][Full Text][PDF]
F. Rauch, H. Plotkin, R. Travers, L. Zeitlin, and F. H. Glorieux Osteogenesis Imperfecta Types I, III, and IV: Effect of Pamidronate Therapy on Bone and Mineral Metabolism
J. Clin. Endocrinol. Metab.,
March 1, 2003;
88(3):
986 - 992.
[Abstract][Full Text][PDF]
J. R. Berenson, B. E. Hillner, R. A. Kyle, K. Anderson, A. Lipton, G. C. Yee, and J. S. Biermann American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma
J. Clin. Oncol.,
September 1, 2002;
20(17):
3719 - 3736.
[Abstract][Full Text][PDF]
O. Johnell, W. H. Scheele, Y. Lu, J.-Y. Reginster, A. G. Need, and E. Seeman Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Postmenopausal Women with Osteoporosis
J. Clin. Endocrinol. Metab.,
March 1, 2002;
87(3):
985 - 992.
[Abstract][Full Text][PDF]
R. Marcus, M. Wong, H. Heath III, and J. L. Stock Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint
Endocr. Rev.,
February 1, 2002;
23(1):
16 - 37.
[Abstract][Full Text][PDF]
P. A. Price, J. R. Buckley, and M. K. Williamson The Amino Bisphosphonate Ibandronate Prevents Vitamin D Toxicity and Inhibits Vitamin D-Induced Calcification of Arteries, Cartilage, Lungs and Kidneys in Rats
J. Nutr.,
November 1, 2001;
131(11):
2910 - 2915.
[Abstract][Full Text][PDF]
P. A. Price, H. H. June, J. R. Buckley, and M. K. Williamson Osteoprotegerin Inhibits Artery Calcification Induced by Warfarin and by Vitamin D
Arterioscler Thromb Vasc Biol,
October 1, 2001;
21(10):
1610 - 1616.
[Abstract][Full Text][PDF]
B. M. Lange, R. E.B. Ketchum, and R. B. Croteau Isoprenoid Biosynthesis. Metabolite Profiling of Peppermint Oil Gland Secretory Cells and Application to Herbicide Target Analysis
Plant Physiology,
September 1, 2001;
127(1):
305 - 314.
[Abstract][Full Text][PDF]
S. M. Ali, F. J. Esteva, G. Hortobagyi, H. Harvey, J. Seaman, R. Knight, L. Costa, and A. Lipton Safety and Efficacy of Bisphosphonates Beyond 24 Months in Cancer Patients
J. Clin. Oncol.,
July 15, 2001;
19(14):
3434 - 3437.
[Abstract][Full Text][PDF]
N. R. Biermasz, N. A. T. Hamdy, Y. J. H. Janssen, and F. Roelfsema Additional Beneficial Effects of Alendronate in Growth Hormone (GH)-Deficient Adults with Osteoporosis Receiving Long-Term Recombinant Human GH Replacement Therapy: A Randomized Controlled Trial
J. Clin. Endocrinol. Metab.,
July 1, 2001;
86(7):
3079 - 3085.
[Abstract][Full Text][PDF]
P. A. Price, S. A. Faus, and M. K. Williamson Bisphosphonates Alendronate and Ibandronate Inhibit Artery Calcification at Doses Comparable to Those That Inhibit Bone Resorption
Arterioscler Thromb Vasc Biol,
May 1, 2001;
21(5):
817 - 824.
[Abstract][Full Text][PDF]
G. G. Reinholz, B. Getz, L. Pederson, E. S. Sanders, M. Subramaniam, J. N. Ingle, and T. C. Spelsberg Bisphosphonates Directly Regulate Cell Proliferation, Differentiation, and Gene Expression in Human Osteoblasts
Cancer Res.,
November 1, 2000;
60(21):
6001 - 6007.
[Abstract][Full Text]
D. M. Nierman and J. I. Mechanick Biochemical Response to Treatment of Bone Hyperresorption in Chronically Critically Ill Patients
Chest,
September 1, 2000;
118(3):
761 - 766.
[Abstract][Full Text][PDF]
J. Hunziker, T. Wronski, and S.C. Miller Mandibular Bone Formation Rates in Aged Ovariectomized Rats Treated with Anti-resorptive Agents Alone and in Combination with Intermittent Parathyroid Hormone
Journal of Dental Research,
June 1, 2000;
79(6):
1431 - 1438.
[Abstract][PDF]
H. Plotkin, F. Rauch, N. J. Bishop, K. Montpetit, J. Ruck-Gibis, R. Travers, and F. H. Glorieux Pamidronate Treatment of Severe Osteogenesis Imperfecta in Children under 3 Years of Age
J. Clin. Endocrinol. Metab.,
May 1, 2000;
85(5):
1846 - 1850.
[Abstract][Full Text]
S. C. Manolagas Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis
Endocr. Rev.,
April 1, 2000;
21(2):
115 - 137.
[Abstract][Full Text]
P. Ravn, S. R. Weiss, J. A. Rodriguez-Portales, M. R. McClung, R. D. Wasnich, N. L. Gilchrist, P. Sambrook, I. Fogelman, D. Krupa, A. J. Yates, et al. Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal
J. Clin. Endocrinol. Metab.,
April 1, 2000;
85(4):
1492 - 1497.
[Abstract][Full Text]
B. E. Hillner, J. N. Ingle, J. R. Berenson, N. A. Janjan, K. S. Albain, A. Lipton, G. Yee, J. S. Biermann, R. T. Chlebowski, and D. G. Pfister American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
J. Clin. Oncol.,
March 13, 2000;
18(6):
1378 - 1391.
[Abstract][Full Text][PDF]
P. Ravn, M. Bidstrup, R. D. Wasnich, J. W. Davis, M. R. McClung, A. Balske, C. Coupland, O. Sahota, A. Kaur, M. Daley, et al. Alendronate and Estrogen-Progestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled Trial
Ann Intern Med,
December 21, 1999;
131(12):
935 - 942.
[Abstract][Full Text][PDF]
A. A. Reszka, J. M. Halasy-Nagy, P. J. Masarachia, and G. A. Rodan Bisphosphonates Act Directly on the Osteoclast to Induce Caspase Cleavage of Mst1 Kinase during Apoptosis. A LINK BETWEEN INHIBITION OF THE MEVALONATE PATHWAY AND REGULATION OF AN APOPTOSIS-PROMOTING KINASE
J. Biol. Chem.,
December 3, 1999;
274(49):
34967 - 34973.
[Abstract][Full Text][PDF]
H. L. Benford, J. C. Frith, S. Auriola, J. Mönkkönen, and M. J. Rogers Farnesol and Geranylgeraniol Prevent Activation of Caspases by Aminobisphosphonates: Biochemical Evidence for Two Distinct Pharmacological Classes of Bisphosphonate Drugs
Mol. Pharmacol.,
July 1, 1999;
56(1):
131 - 140.
[Abstract][Full Text]
